Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery

Cancer Gene Therapy

Volumn 23, Issue 5, 2016, Pages 142-148

  Katz, S C ^a,b   Point, G R ^a   Cunetta, M ^a   Thorn, M ^a   Guha, P ^a   Espat, N J ^a,b   Boutros, C ^c   Hanna, N ^c   Junghans, R P ^d  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2; BIOLOGICAL MARKER; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TAIL VEIN; TARGET CELL; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL THERAPY; CYTOTOXICITY; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY; PERITONEAL NEOPLASMS; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS; CELL- AND TISSUE-BASED THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; MICE; PERITONEAL NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84963543352     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.14     Document Type: Article

References (23)

1. Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C et al. Peritoneal carcinomatosis. World J Gastroenterol 2013; 19: 6979-6994.
2. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
3. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
4. Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-2165.
5. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015; 21: 3149-3159.
6. Saied A, Licata L, Burga RA, Thorn M, McCormack E, Stainken BF et al. Neutrophil: lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther 2014; 21: 457-462.
7. Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Imunol Immunother 2015; 64: 817-829.
8. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348: 62-68.
9. Saied A, Pillarisetty VG, Katz SC. Immunotherapy for solid tumors-a review for surgeons. J Surg Res 2014; 187: 525-535.
10. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/TCRzeta designer T cells for treatment of melanoma and other neuroectodermal tumors. Clin Cancer Res 2010; 16: 2769-2780.
11. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006; 20: 1819-1828.
12. Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. Curr Opin Mol Ther 2010; 12: 55-63.
13. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013; 62: 1137-1148.
14. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13: 525-541.
15. Thorn M, Point GR, Burga RA, Nguyen CT, Joseph Espat N, Katz SC. Liver metas-tases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells. J Leukoc Biol 2014; 96: 883-894.
16. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res 2011; 71: 2871-2881.
17. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6: 261ra151.
18. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
19. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015; 3: 610-619.
20. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-745.
21. John LB, Devaud C, Duong CM, Yong C, Beavis PA, Haynes NM et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19: 5636-5646.
22. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 2009; 21: 1065-1077.
23. Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 2013; 91: 493-502.